Hamilton Elementary, Moline, chosen as Model School
Hamilton Elementary School, Moline, has announced its selection as a Model School at the 2025 Model Schools Conference in Washington, D.C., June 22-25, a news release says.
Hosted by the Center for Model Schools, this highly anticipated event honors forward-thinkingschools that drive transformation, inspire change, and implement groundbreaking strategies toimprove student outcomes.
Chosen from a competitive group of schools nationwide, Hamilton has demonstrated anunwavering commitment to student success and innovation. By fostering a culture ofcollaboration, ambitious instruction, and continuous improvement, the school exemplifiesexcellence in education.
'We are honored to be recognized as a Model School,' said Lynsy Oswald, principal atHamilton Elementary School. 'Every child deserves a learning environment that is welcoming toall families, has high expectations for student achievement, and has a strong sense ofbelonging. Our staff goes above and beyond to provide this. I feel very fortunate to work with the best.'
As part of this recognition, Hamilton Elementary School will present at MSC 2025, engaging with more than 5,000 educators to share insights on their success. Last year, the Moline-Coal Valley School District was designated as an Innovative District at the 2024 Model Schools Conference held in June. Three district leaders presented on 'Prioritizing Culture to Drive Student Achievement,' engaging with educators and enabling them to learn how to embrace the power of creating culture led by data to maximize personalized learning. The three presenters included Brian Prybil, deputy superintendent; Oswald, and Steven Etheridge, former principal of Bicentennial Elementary and now director of elementary education.
About the Center for Model Schools
The Center for Model Schools, a division of HMH, is the only organization devoted to providingyear-round leadership support through its namesake Model Schools Conference, leadershipcohorts, and 1:1 consulting. Each team member at The Center for Model Schools has a proven history of successfully driving student growth – with specializations that include creating equitable and inclusive learning environments and building cultures of collaboration.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
19 hours ago
- Forbes
What's Next For ArcelorMittal Stock After A 35% Rally?
HAMILTON, CANADA - JUNE 9: Steel coils are seen in a yard at ArcelorMittal Dofasco's steel mill on ... More June 9, 2025 in Hamilton, Canada. (Photo by) ArcelorMittal (NYSE:MT) has experienced a notable rise recently. Following a period of poor performance, the world's second-largest steel manufacturer has rebounded with better earnings and a strong strategic focus. In Q1 2025, the company reported an EBITDA of $1.58 billion, which exceeded expectations, driven by increased iron ore production (particularly in Liberia) and stable steel shipments. This development has boosted investor confidence — the stock has risen 35% year-to-date. Buy Or Sell MT Stock? What is fueling this turnaround? Several key factors. First, global steel demand (excluding China) is projected to grow by 2.5–3.5% this year, and ArcelorMittal is strategically positioned to capitalize on this trend, thanks to its presence in rapidly expanding markets like India and infrastructure-heavy regions such as the U.S. The company is also making smart investments — boosting capacity, modernizing facilities (such as the electric arc furnace in Alabama), and increasing high-grade iron ore exports. For investors seeking potential gains with reduced volatility, the High Quality portfolio has significantly outperformed the S&P 500, achieving over 91% returns since inception. Nevertheless, it's not completely smooth sailing. Steel prices are often cyclical, and with global trade tensions escalating — particularly between the U.S. and China — market sentiment can change quickly. Additionally, the transition to green steel in Europe will necessitate substantial investments and may exert pressure on margins in the short term. The bottom line? ArcelorMittal stock seems to have much of the short-term optimism already reflected in its price. With a modest forward P/S ratio of around 0.4x over the past twelve months, it still appears inexpensive on paper — however, with rising expectations, limited earnings surprise potential, and macroeconomic risks (including tariffs and steel price fluctuations), any further upside may come gradually unless new growth catalysts arise. In summary, MT appears fairly valued currently, with gains already factored in unless supportive conditions improve. For further insights, see our analysis on ArcelorMittal Valuation: Is MT Stock Expensive Or Cheap?, which details our valuation rationale for ArcelorMittal. Additionally, check out our analysis of ArcelorMittal revenues for more information on the company's primary revenue streams and their expected trends. Investing in a single stock like MT carries risks. Conversely, the Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has consistently outperformed the S&P 500 over the past 4 years. Why is that? As a collective, HQ Portfolio stocks have delivered superior returns with reduced risk compared to the benchmark index, offering a smoother ride as demonstrated in HQ Portfolio performance metrics.
Yahoo
2 days ago
- Yahoo
DHT Holdings, Inc. announces agreement to acquire a 2018 built VLCC
HAMILTON, BERMUDA, June 19, 2025 – DHT Holdings, Inc. (NYSE:DHT) ('DHT' or the 'Company') today announces that it has entered into an agreement to acquire a VLCC built in 2018 at Hyundai Heavy Industries (HHI), for $107 million. The vessel is scheduled to deliver towards the end of the third quarter of 2025. The acquisition will be financed through the Company's available liquidity and projected mortgage debt. The vessel was built to a high specification by its current owner and is fitted with an exhaust gas cleaning system. The acquisition will improve DHT's age profile and will further improve the DHT fleet's efficiency metrics. DHT's President & CEO, Svein Moxnes Harfjeld, comments: 'We are always looking for opportunities with the intent of improving earnings per share for our shareholders. This is a sister of vessels built by us in 2018, a design with large carrying capacity and premium earning capabilities, well suited for the trading patterns of our key customers. We believe this to be a fitting addition to our fleet, replacing some of the earnings capacity that has been divested this year, delivering into a market with attractive prospects.' About DHT Holdings, is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our wholly owned management companies in Monaco, Norway, Singapore, and India. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles; our fleet employment with a combination of market exposure and fixed income contracts; our disciplined capital allocation strategy through cash dividends, investments in vessels, debt prepayments and share buybacks; and our transparent corporate structure maintaining a high level of integrity and corporate governance. For further information please visit Forward Looking StatementsThis press release contains certain forward-looking statements and information relating to the Company that are based on beliefs of the Company's management as well as assumptions, expectations, projections, intentions and beliefs about future events. When used in this document, words such as 'believe,' 'intend,' 'anticipate,' 'estimate,' 'project,' 'forecast,' 'plan,' 'potential,' 'will,' 'may,' 'should' and 'expect' and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. These statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent the Company's estimates and assumptions only as of the date of this press release and are not intended to give any assurance as to future results. For a detailed discussion of the risk factors that might cause future results to differ, please refer to the Company's Annual Report on Form 20-F, filed with the SEC on March 20, 2025. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur, and the Company's actual results could differ materially from those anticipated in these forward-looking statements. Contact:Laila C. Halvorsen, CFOPhone: +1 441 295 1422 and +47 984 39 935 E-mail: lch@
Yahoo
2 days ago
- Yahoo
Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference
Key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency (PDCD) were presented. ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, June 19, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the presentation of key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency (PDCD) at the Mitochondrial Medicine 2025 conference in St. Louis. "We are pleased to have Dr. Peter Stacpoole share the latest data from our clinical trial at the Mitochondrial Medicine conference," said Dave Penake, CEO Saol Therapeutics. "We would like to thank patients, investigators and clinical trial sites who participated in the clinical trial. Our team is working with the FDA on the review of this product, with an FDA action date of August 27th, 2025." Key findings from the trial include: DCA was well-tolerated, even upon chronic administration for over three years. The most commonly reported adverse reaction occurring in >5% of patients was gastrointestinal disorders (n=2, 5.9%). The primary efficacy endpoint, the Observer Reported Outcome (ObsRO) survey, did not demonstrate statistical significance in the double-blind portion of the trial. Longer duration of therapy, including the open label extension (OLE), demonstrated a statistically significant improvement in motor function in the ITT population (p=0.002). DCA significantly (p=0.006) decreased plasma lactate concentrations. DCA treatment improved survival (p=0.027) compared to appropriately matched controls. Saol Therapeutics, Dr. Peter Stacpoole, and the other investigators plan to submit the results of the Phase III clinical program for publication. SL1009, Sodium Dichloroacetate (DCA) DCA is an investigational product that, if approved, will be used with a proprietary dose-determining genetic test to treat an orphan pediatric-onset mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD). PDCD is a rare and life-threatening genetic disorder that can cause chronic energy deficit leading to lactic acidosis, profound developmental problems and early childhood death. DCA has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, making it eligible for Priority Review and a Priority Review Voucher. The FDA action or PDUFA date is August 27, 2025. Saol, in collaboration with Medosome Biotec, also filed the Humanitarian Device Exemption (HDE) application for the dose-determining genetic test that will serve as a required companion diagnostic for patients treated with DCA. For PDCD patients who did not participate in the clinical trial, Saol is now conducting an expanded access program (EAP) for eligible PDCD patients. More information can be found at NCT06931262. About Saol TherapeuticsSaol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations. For more information, visit Saol Therapeutics ContactSenior Vice President, StrategyBrian Nappi bnappi@ ST-P207-3011-01 View original content to download multimedia: SOURCE Saol Therapeutics Sign in to access your portfolio
